EUVIMEDEUVIMED entdecken
Klinische Studie (Phase I)Multizentrische StudieOpen Access · CC BY 4.0

Pharmacokinetics, safety, and tolerability of ceftibuten-ledaborbactam etzadroxil in participants with renal impairment

Carlos Fernando de Oliveira iD, Kathryn Lowe, Penny Fatato, Thomas Marbury, Karine Litherland iD, Marc Engelhardt iD, Kamal A Hamed iD, Paul C McGovern iD

Antimicrobial Agents and Chemotherapy · 04.11.2026 · 70 (11)

DOI: 10.1128/aac.00860-26 ↗

Kurz gefasst

Klinische Studie (Phase I) in der Zeitschrift Antimicrobial Agents and Chemotherapy, erschienen am 04.11.2026. Verfasst von Carlos Fernando de Oliveira und 7 weiteren Autor:innen. Beteiligte Einrichtung: De Oliveira Consulting LLC, New Hope, Pennsylvania, USA. Hauptthemen laut MEDLINE: Anti-Bacterial Agents, Ceftibuten, Cephalosporins, Renal Insufficiency. Die Arbeit nennt 18 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: NIH HHS, National Institute of Allergy and Infectious Diseases, Venatorx Pharmaceuticals, Inc..

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Ledaborbactam etzadroxil is an orally bioavailable prodrug of ledaborbactam, a broad-spectrum β-lactamase inhibitor being developed in combination with ceftibuten for the treatment of complicated urinary tract infections caused by antibiotic-resistant pathogens. As both agents are primarily eliminated via renal excretion, dose adjustment may be required in patients with impaired renal function. This phase 1 study ( NCT05488678 ) evaluated the pharmacokinetics and safety of ceftibuten and ledaborbactam etzadroxil in participants with normal renal function; mild, moderate, or severe renal impairment; or end-stage renal disease (ESRD) undergoing hemodialysis. Participants received a single dose of ceftibuten-ledaborbactam etzadroxil (600 mg/600 mg); those with ESRD received doses both before and after hemodialysis. Among 32 enrolled participants, the mean age was 62.2 years, and 81.3% were male. For both ceftibuten and ledaborbactam, decreasing renal function was associated with increased plasma exposure and reduced renal clearance (CLr). In participants with mild, moderate, or severe renal impairment, plasma exposure of ceftibuten increased 1.3-, 2.3-, and 3.7-fold, respectively, and ledaborbactam increased 1.5-, 1.9-, and 4.4-fold, respectively. Ceftibuten CLr decreased from 2.2 L/h in participants with normal function to 0.3 L/h in those with severe impairment, while ledaborbactam CLr decreased from 3.0 to 0.5 L/h. In participants with ESRD, both drugs were moderately removed (23% and 38% for ceftibuten and ledaborbactam, respectively) by hemodialysis. No deaths, serious adverse events, or treatment-related adverse events leading to study drug discontinuation were reported. These results indicate that dose adjustment of ceftibuten-ledaborbactam etzadroxil will be required for patients with reduced renal function. This study is registered with ClinicalTrials.gov as NCT05488678 .

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Anti-Bacterial AgentsCeftibutenCephalosporinsRenal InsufficiencyAgedFemaleHumansMaleMiddle AgedKidney Failure, ChronicRenal DialysisThird Generation Cephalosporins

Stichwörter der Autor:innen

ceftibuten-ledaborbactam etzadroxilpharmacokineticsrenal impairmentsafetytolerability

Substanzen

Anti-Bacterial AgentsCeftibutenCephalosporinsThird Generation Cephalosporins

Autor:innen und Institutionen

  • De Oliveira Consulting LLC, New Hope, Pennsylvania, USA.
  • Venatorx Pharmaceuticals, Inc., Malvern, Pennsylvania, USA.
  • Orlando Clinical Research Center, Orlando, Florida, USA.
  • Basilea Pharmaceutica International Ltd, Allschwil, Switzerland.
  • McGovern ID Consulting LLC, Berwyn, Pennsylvania, USA.

ORCID-Profile: Carlos Fernando de Oliveira, Karine Litherland, Marc Engelhardt, Kamal A Hamed, Paul C McGovern

Förderung

  • NIH HHS
  • National Institute of Allergy and Infectious Diseases
  • Venatorx Pharmaceuticals, Inc.

Zitieren

APA

de Oliveira, C. F., Lowe, K., Fatato, P., Marbury, T., Litherland, K., Engelhardt, M., Hamed, K. A., & McGovern, P. C. (2026). Pharmacokinetics, safety, and tolerability of ceftibuten-ledaborbactam etzadroxil in participants with renal impairment. Antimicrobial Agents and Chemotherapy, 70(11). https://doi.org/10.1128/aac.00860-26

Vancouver

de Oliveira CF, Lowe K, Fatato P, Marbury T, Litherland K, Engelhardt M, et al. Pharmacokinetics, safety, and tolerability of ceftibuten-ledaborbactam etzadroxil in participants with renal impairment. Antimicrobial Agents and Chemotherapy. 2026;70(11). doi:10.1128/aac.00860-26

BibTeX
@article{deOliveira2026,
  author = {de Oliveira, Carlos Fernando and Lowe, Kathryn and Fatato, Penny and Marbury, Thomas and Litherland, Karine and Engelhardt, Marc and Hamed, Kamal A and McGovern, Paul C},
  title = {Pharmacokinetics, safety, and tolerability of ceftibuten-ledaborbactam etzadroxil in participants with renal impairment},
  journal = {Antimicrobial Agents and Chemotherapy},
  year = {2026},
  volume = {70},
  number = {11},
  doi = {10.1128/aac.00860-26}
}
Kostenlos starten →